Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis

被引:71
|
作者
Sanguankeo, Anawin [1 ,2 ,3 ]
Upala, Sikarin [1 ,2 ]
Cheungpasitporn, Wisit [4 ]
Ungprasert, Patompong [5 ]
Knight, Eric L. [6 ]
机构
[1] Columbia Univ Coll Phys & Surg, Bassett Med Ctr, Dept Internal Med, Cooperstown, NY USA
[2] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Prevent & Social Med, Bangkok 10700, Thailand
[3] Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA
[4] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN USA
[5] Mayo Clin, Div Rheumatol, Rochester, MN USA
[6] Columbia Univ Coll Phys & Surg, Bassett Med Ctr, Div Nephrol, Cooperstown, NY USA
来源
PLOS ONE | 2015年 / 10卷 / 07期
关键词
PROGRESSION; THERAPY; PRAVASTATIN; PEOPLE; ROSUVASTATIN; ATORVASTATIN; CARE;
D O I
10.1371/journal.pone.0132970
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background HMG CoA reductase inhibitors (statins) are known to prevent cardiovascular disease and improve lipid profiles. However, the effects of statins on renal outcomes, including decline in estimated glomerular filtration rate (eGFR) and proteinuria in patients with chronic kidney disease (CKD), are controversial. This meta-analysis evaluated the impact of statins on renal outcomes in patients with CKD. Materials and Methods We comprehensively searched the databases of MEDLINE, EMBASE, and Cochrane Databases. The inclusion criteria were published RCT and cohort studies comparing statin therapy to placebo or active controls in patients with CKD (eGFR <60 ml/min/1.73 m(2)) not requiring dialysis. The primary outcome was the differences in the change of eGFR. We also examined change of protein concentration in urine as a secondary outcome. A meta-analysis comparing statin and its control groups and a subgroup analysis examining intensity of statin were performed. Results From 142 full-text articles, 10 studies were included in the meta-analysis. Overall, there was a significant difference in rate of eGFR change per year favoring statin group (mean difference (MD) = 0.10 ml/min/1.73 m(2), 95% CI: 0.09 to 0.12). In our subgroup analysis, those who received high-intensity statins had a significant difference in eGFR with a MD of 3.35 (95% CI: 0.91 to 5.79) ml/min/1.73 m(2) compared to control. No significant change in eGFR was found with moderate-and low-intensity statin therapy. Compared with the control group, the statin group did not have a difference in reduction of proteinuria with MD in change of proteinuria of 0.19 gm/day (95% CI: -0.02 to 0.40). Conclusion Overall, there was a difference in change of eGFR between the statin and control group. High-intensity statins were found to improve a decline in eGFR in population with CKD not requiring dialysis compared with control, but moderate- and low-intensity statins were not. Statins were not found to decrease proteinuria in patients with CKD.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis
    Hou, Wanyin
    Lv, Jicheng
    Perkovic, Vlado
    Yang, Lihong
    Zhao, Na
    Jardine, Meg J.
    Cass, Alan
    Zhang, Hong
    Wang, Haiyan
    EUROPEAN HEART JOURNAL, 2013, 34 (24) : 1807 - +
  • [32] Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis
    Tahir Kanji
    Mandark Gandhi
    Catherine M Clase
    Robert Yang
    BMC Nephrology, 16
  • [33] EFFECTS OF INTENSIVE BLOOD PRESSURE LOWERING ON KIDNEY DISEASE PROGRESSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Wu, Hon-Yen
    Tsai, Wan-Chuan
    Peng, Yu-Sen
    Hung, Kuan-Yu
    Chien, Kuo-Liong
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [34] The Prevalence and Severity of Chronic Pain in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
    Davison, Sara N.
    Rathwell, Sarah
    Ghosh, Sunita
    George, Chelsy
    Pfister, Ted
    Dennett, Liz
    CANADIAN JOURNAL OF KIDNEY HEALTH AND DISEASE, 2021, 8
  • [35] Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials
    Strippoli, Giovanni F. M.
    Navaneethan, Sankar D.
    Johnson, David W.
    Perkovic, Vlado
    Pellegrini, Fabio
    Nicolucci, Antonio
    Craig, Jonathan C.
    BMJ-BRITISH MEDICAL JOURNAL, 2008, 336 (7645): : 645 - 651
  • [36] Effects of the Huangkui capsule (sic) on chronic kidney disease: a systematic review and Meta-analysis
    Li, Wei
    Xia, Ping
    Sun, Wei
    Zhao, Jing
    Liu, Qiong
    Geng, Lianyi
    Zhou, Yao
    Gao, Kun
    JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2023, 43 (01) : 6 - 13
  • [37] Concurrent chronic kidney disease in patients with inflammatory bowel disease, a systematic review and meta-analysis
    Han, Xiaoping
    Xu, Zifeng
    Chang, Yu
    Li, Hongyan
    Hu, Sileng
    Chang, Shiyu
    Liu, Yue
    Yu, Chanjiao
    Tang, Tongyu
    Li, Yuqin
    FRONTIERS IN MEDICINE, 2024, 11
  • [38] The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis
    Zheng, Yi-Xiang
    Zhou, Peng-Cheng
    Zhou, Rong-Rong
    Fan, Xue-Gong
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 29 (07) : 759 - 766
  • [39] Circulating irisin level in chronic kidney disease patients: a systematic review and meta-analysis
    Gan, Wenyuan
    Chen, Wenli
    Li, Tianyu
    Shao, Danni
    Xu, Fang
    Huo, Shanshan
    Li, Chenchen
    Yang, Zhenhua
    Zeng, Xingruo
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (06) : 1295 - 1302
  • [40] Periodontitis and risk of mortality in patients with chronic kidney disease: A systematic review with meta-analysis
    Wu, Hong
    Wang, Shengpeng
    Wei, Zhenhui
    JOURNAL OF PERIODONTAL RESEARCH, 2024, 59 (05) : 868 - 876